Repository logoGCRIS
  • English
  • Türkçe
  • Русский
Log In
Have you forgotten your password?
Home
Communities
Browse GCRIS
Entities
Overview
GCRIS Guide
Erzurum City Archive
  1. Home
  2. Browse by Author

Browsing by Author "Klevstig, Martina"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Article
    Discovery of Therapeutic Agents Targeting Pklr for NAFLD Using Drug Repositioning
    (Elsevier, 2022) Zhang, Cheng; Shi, Mengnan; Kim, Woonghee; Arif, Muhammad; Klevstig, Martina; Li, Xiangyu; Yildtrim, Serkan
    Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver pathologies. However, no medical treatment has been approved for the treatment of NAFLD. In our previous study, we found that PKLR could be a potential target for treatment of NALFD. Here, we investigated the effect of PKLR in in vivo model and performed drug repositioning to identify a drug candidate for treatment of NAFLD. Methods Tissue samples from liver, muscle, white adipose and heart were obtained from control and PKLR knock-out mice fed with chow and high sucrose diets. Lipidomics as well as transcriptomics analyses were conducted using these tissue samples. In addition, a computational drug repositioning analysis was performed and drug candidates were identified. The drug candidates were both tested in in vitro and in vivo models to evaluate their toxicity and efficacy. Findings The Pklr KO reversed the increased hepatic triglyceride level in mice fed with high sucrose diet and partly recovered the transcriptomic changes in the liver as well as in other three tissues. Both liver and white adipose tissues exhibited dysregulated circadian transcriptomic profiles, and these dysregulations were reversed by hepatic knockout of Pklr. In addition, 10 small molecule drug candidates were identified as potential inhibitor of PKLR using our drug repositioning pipeline, and two of them significantly inhibited both the PKLR expression and triglyceride level in in vitro model. Finally, the two selected small molecule drugs were evaluated in in vivo rat models and we found that these drugs attenuate the hepatic steatosis without side effect on other tissues. Interpretation In conclusion, our study provided biological insights about the critical role of PKLR in NAFLD progression and proposed a treatment strategy for NAFLD patients, which has been validated in preclinical studies. Copyright (C) 2022 The Authors. Published by Elsevier B.V.
  • Loading...
    Thumbnail Image
    Correction
    Discovery of Therapeutic Agents Targeting Pklr for NAFLD Using Drug Repositioning ( Vol 83 , 104214 , 2022)
    (Elsevier, 2024) Zhang, Cheng; Shi, Mengnan; Kim, Woonghee; Arif, Muhammad; Klevstig, Martina; Li, Xiangyu; Mardinoglu, Adil
Repository logo
Collections
  • Scopus Collection
  • WoS Collection
  • TrDizin Collection
  • PubMed Collection
Entities
  • Research Outputs
  • Organizations
  • Researchers
  • Projects
  • Awards
  • Equipments
  • Events
About
  • Contact
  • GCRIS
  • Research Ecosystems
  • Feedback
  • OAI-PMH

Log in to GCRIS Dashboard

GCRIS Mobile

Download GCRIS Mobile on the App StoreGet GCRIS Mobile on Google Play

Powered by Research Ecosystems

  • Privacy policy
  • End User Agreement